JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

Home・Akcijų sąrašas・Immunocore Holdings PLC ADR

Immunocore Holdings PLC ADR

Uždarymo kaina

28 0.32

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

27.88

Max

28.3

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-30M -30M
Pardavimai	-26M 77M
Pelno marža	-38.823
Darbuotojai	524
EBITDA	-12M -8M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+122.55% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-212M 1.5B
Ankstesnė atidarymo kaina	27.68
Ankstesnė uždarymo kaina	28

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bearish Evidence

27.895 / 30.16 Palaikymas ir pasipriešinimas

Immunocore Holdings PLC ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-01 21:36; UTC

Įsigijimai, susijungimai, perėmimai

FTC Requires 365 Retail Markets to Divest Micromarket Kiosk Business to Clear Acquisition of Cantaloupe

2026-05-01 20:40; UTC

Įsigijimai, susijungimai, perėmimai

Meta Platforms Acquires Humanoid Robot Startup Assured Robot Intelligence

2026-05-01 18:37; UTC

Pagrindinės rinkos jėgos

Senseonic Shares Slide on Underwritten Offering Price

2026-05-01 16:46; UTC

Pagrindinės rinkos jėgos

Stellantis, Ferrari Fall on Trump Plan to Increase Tariff on European Cars, Trucks

2026-05-02 19:57; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire CEO Greg Abel Takes the Stage, Making a Case for the Post-Buffett Era -- 3rd Update

2026-05-02 15:24; UTC

Uždarbis

Berkshire CEO Greg Abel Takes the Stage, Talks Through Quarterly Results -- Update

2026-05-02 12:46; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Berkshire Profits More Than Double on Gains in Insurance, Railroad, Energy Businesses -- WSJ

2026-05-02 08:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-05-01 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-05-01 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-01 20:42; UTC

Uždarbis

Western Digital Beats Earnings Estimates. The Stock Is Falling Anyway. -- Barrons.com

2026-05-01 19:33; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-01 19:33; UTC

Rinkos pokalbiai

Change in Fed Leadership May Hamper Crypto Rebound -- Market Talk

2026-05-01 19:18; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Rises for Second Consecutive Week Amid Middle East Standoff -- Market Talk

2026-05-01 19:13; UTC

Rinkos pokalbiai

Natural Gas Rises as Markets Wait for Warmer Temperatures -- Market Talk

2026-05-01 18:36; UTC

Uždarbis

3 Takeaways From Apple Earnings. The Stock Is Surging. -- Barrons.com

2026-05-01 18:35; UTC

Uždarbis

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

2026-05-01 18:28; UTC

Uždarbis

These Stocks Are Today's Movers: Apple, Sandisk, Roblox, Intel, Ferrari, Atlassian, Western Digital, Clorox, Paramount Skydance, and More -- Barrons.com

2026-05-01 18:27; UTC

Rinkos pokalbiai

Gold and Silver Higher for the Day, Lower For The Week -- Market Talk

2026-05-01 18:14; UTC

Įsigijimai, susijungimai, perėmimai

Barclays Completes Acquisition of Best Egg

2026-05-01 18:04; UTC

Uždarbis

The First $6 Trillion Company May Not Be Nvidia -- Barrons.com

2026-05-01 17:43; UTC

Rinkos pokalbiai

Home Sales in San Francisco Jump 22.2% in March -- Market Talk

2026-05-01 17:37; UTC

Rinkos pokalbiai

Crypto 'Fear and Greed Index' Returns to Neutral Reading After Brief Dip -- Market Talk

2026-05-01 17:30; UTC

Rinkos pokalbiai

Uždarbis

Apple's 2Q Print, 3Q Guide Set Up Stock to Outperform -- Market Talk

2026-05-01 17:28; UTC

Rinkos pokalbiai

Uždarbis

Apple's Shift From Net Cash Neutral Goal Seen as Cryptic Signal -- Market Talk

2026-05-01 17:21; UTC

Rinkos pokalbiai

Uždarbis

Apple Seen Absorbing Higher Memory Costs -- Market Talk

2026-05-01 17:19; UTC

Rinkos pokalbiai

Svarbiausios naujienos

U.S. Oil Rig Count Rises by 1 to 408 -- Market Talk

2026-05-01 16:38; UTC

Rinkos pokalbiai

Institutional Markets Begin to Trade on Event Contracts -- Market Talk

2026-05-01 16:23; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Skydance Gets a Double Upgrade. It's the Warner Bros. Deal. -- Barrons.com

2026-05-01 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Immunocore Holdings PLC ADR Prognozė

Kainos tikslas

By TipRanks

122.55% į viršų

12 mėnesių prognozė

Vidutinis 62.67 USD 122.55%

Aukščiausias 100 USD

Žemiausias 33 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Immunocore Holdings PLC ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

9 ratings

Pirkti

Laikyti

Parduoti

Remiantis 9 analitikų, pateikusių Immunocore Holdings PLC ADR akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

27.895 / 30.16Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

There is one bearish event.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.